“…The oral administration of soybean saponin did not influence TG, TC, HDL-C and glucose; however, the average LDL-C, AST, ALT, and BUN values in the saponin group were lower than those in the control group (29.4%, 31.7%, 18.2%, and 14.6% lower, respectively). The LDL-Clowering effect and liver injury-preventive effect of soyasaponin in laboratory animals have already been reported; 5,11,12) however, little is known about the effect of reducing the marker of kidney function (i.e., BUN) by soybean saponin. Soybean saponin may possibly protect the kidneys from hypertensive damage by reducing the BP level.…”